Founded in 1992 in Houston, Texas, Fabre-Kramer
Pharmaceuticals focuses on compounds to license-in, develop for
global registration, and license-out to commercial partners. Fabre-Kramer
then creates life-cycle management strategies to maximize the
commercial potential of those compounds.
Fabre-Kramer Pharmaceuticals forms partnerships with individual
researchers, research institutions, pharmaceutical as well as
biotechnology companies, to license in molecules for development
and further license them out for commercialization.
FKP's main therapeutic areas of activity are psychiatry and neurology.
Once a candidate is licensed-in, a dedicated, experienced, and
multidisciplinary project management team is established to obtain marketing authorizations in major markets, i.e. North
America, Europe and Japan.
Shared Objectives with Licensors
As Fabre-Kramer Pharmaceuticals does not conduct sales and marketing,
only a rapid and successful registration, along with superior
marketing guarantee the company’s return on investment,
sustainability, and viability. Fabre-Kramer grants a significant share
of downstream profits to the licensor.
GlaxoSmithKline, Bristol-Myers Squibb, Schering-Plough, and Pfizer